References
- DrugsData.org: GC/MS laboratory testing results. Erowid Center. 2020 [accessed 2020 Nov 20]. Available from: https://drugsdata.org/view.php?id=8783,8785.
- Dwoskin LP, Rauhut AS, King-Popisil KA, et al. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006;12(3–4):178–207.
- Dasgupta N, Sayegh J, Menone C, et al. Using social listening data to monitor misuse and nonmedical use of bupropion: a content analysis. JMIR Public Health Surveill. 2017;3(1):e6.
- Hillard WT, Barloon L, Farley P, et al. Bupropion diversion and misuse in the correctional facility. 2013 [accessed 2020 Nov 20]. Available from: https://journals.sagepub.com/doi/https://doi.org/10.1177/1078345813486448.
- Stassinos GL, Klein-Schwartz W. Bupropion “abuse” reported to US poison centers. J Addict Med. 2016;10(5):357–362.
- Baribeau D, Araki KF. Intravenous bupropion: a previously undocumented method of abuse of a commonly prescribed antidepressant agent. J Addict Med. 2013;7(3):216–217.
- Kim D, Steinhart B. Seizures induced by recreational abuse of bupropion tablets via nasal insufflation. CJEM. 2010;12(2):158–161.
- Yoon G, Westermeyer J. Intranasal bupropion abuse: case report. Am J Addict. 2013;22(2):180–180.